Symphogen leads the field of mAb mixtures and is developing a variety of products for multiple oncology indications, alone and in partnership. Validating strategic partnerships has been entered with Shire (former Baxalta) and Genentech.

We continue to seek value-generating partnerships, including with large biotechnology and pharmaceutical companies with late stage development and commercialization capabilities, to leverage our internal capabilities.

Business Development Inquiries:

Jette Asboe Lassen, 
VP,  Business Development 
Pederstrupvej 93 
DK-2750 Ballerup